Journal of Korean Neurosurgical Society

The Korean Neurosurgical Society (대한신경외과학회)
권호 표지
DOI QR코드

DOI QR Code

Chemotherapy for Malignant Gliomas Based on Histoculture Drug Response Assay : A Pilot Study

  • Gwak, Ho-Shin (Department of Neuro-Oncology Clinic, National Cancer Center) ;
  • Park, Hyeon-Jin (Center for Pediatric Oncology, National Cancer Center) ;
  • Yoo, Heon (Department of Neuro-Oncology Clinic, National Cancer Center) ;
  • Youn, Sang-Min (Department of Neurosurgery, Korea Institute of Radiological and Medical Science) ;
  • Rhee, Chang-Hun (Department of Neurosurgery, Korea Institute of Radiological and Medical Science) ;
  • Lee, Seung-Hoon (Department of Neuro-Oncology Clinic, National Cancer Center)
  • Received : 2011.06.23
  • Accepted : 2011.11.21
  • Published : 2011.11.28
Download PDF
⟨ Previous Next ⟩

Abstract

Objective : The Histoculture Drug Response Assay (HDRA), which measures chemosensitivity using minced tumor tissue on drug-soaked gelfoam, has been expected to overcome the limitations of in vitro chemosensitivity test in part. We analyzed interim results of HDRA in malignant gliomas to see if the test can deserve further clinical trials. Methods : Thirty-three patients with malignant gliomas were operated and their tumor samples were examined for the chemosensitivity to 10 chosen drugs by HDRA. The most sensitive chemotherapy regimen among those pre-established was chosen based on the number of sensitive drugs or total inhibition rate (IR) of the regimen. The response was evaluated by 3 month magnetic resonance image. Results : Among 13 patients who underwent total resection of the tumor, 12 showed no evidence of disease and one patient revealed progression. The response rate in 20 patients with residual tumors was 55% (3 complete and 8 partial responses). HDRA sensitivity at the cut-off value of more than one sensitive drug in the applied regimen showed a sensitivity of 100%, specificity of 60% and predictability of 70%. Another cut-off value of >80% of total IR revealed a sensitivity of 100%, specificity of 69%, and predictability of 80%. For 12 newly diagnosed glioblastoma patients, median progression-free survival of the HDRA sensitive group was 21 months, while that of the non-sensitive group was 6 months ($p$=0.07). Conclusion : HDRA for malignant glioma was inferred as a feasible method to predict the chemotherapy response. We are encouraged to launch phase 2 clinical trial with chemosensitivity on HDRA.

Keywords

References

  1. Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, et al. : Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay : clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 55 : 5276-5282, 1995
  2. Bogdahn U : Chemosensitivity of malignant human brain tumors. Preliminary results. J Neurooncol 1 : 149-166, 1983
  3. Boiardi A, Eoli M, Salmaggi A, Pollo B, Milanesi I, Broggi G, et al. : Cisplatin and BCNU chemotherapy for anaplastic oligoastrocytomas. J Neurooncol 49 : 71-75, 2000 https://doi.org/10.1023/A:1006489919811
  4. Choi IS, Lee SH, Kim TY, Bang JS, Paek SH, Kim S, et al. : Phase II study of chemotherapy with ACNU plus cisplatin followed by cranial irradiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 60 : 171-176, 2002 https://doi.org/10.1023/A:1020605617452
  5. Fine HA, Dear KB, Loeffler JS, Black PM, Canellos GP : Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 71 : 2585-2597, 1993 https://doi.org/10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S
  6. Furukawa T, Kubota T, Hoffman RM : Clinical applications of the histoculture drug response assay. Clin Cancer Res 1 : 305-311, 1995
  7. Furukawa T, Kubota T, Watanabe M, Takahara T, Yamaguchi H, Takeuchi T, et al. : High in vitro-in vivo correlation of drug response using sponge-gel-supported three-dimensional histoculture and the MTT end point. Int J Cancer 51 : 489-498, 1992 https://doi.org/10.1002/ijc.2910510325
  8. Gilbert M, O'Neill A, Grossman S, Grunnet M, Mehta M, Jubelirer S, et al. : A phase II study of preradiation chemotherapy followed by external beam radiotherapy for the treatment of patients with newly diagnosed glioblastoma multiforme : an Eastern Cooperative Oncology Group study (E2393). J Neurooncol 47 : 145-152, 2000 https://doi.org/10.1023/A:1006402123397
  9. Grossman SA, O'Neill A, Grunnet M, Mehta M, Pearlman JL, Wagner H, et al. : Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme : Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21 : 1485-1491, 2003 https://doi.org/10.1200/JCO.2003.10.035
  10. Grossman SA, Wharam M, Sheidler V, Kleinberg L, Zeltzman M, Yue N, et al. : Phase II study of continuous infusion carmustine and cisplatin followed by cranial irradiation in adults with newly diagnosed high-grade astrocytoma. J Clin Oncol 15 : 2596-2603, 1997 https://doi.org/10.1200/JCO.1997.15.7.2596
  11. Guo HY, Colangelo D, Li L, Connors KM, Kubota T, Hoffman RM : In vitro histoculture of human tumors with fluorescent dye end-points measured by confocal microscopy : high correlation of in vitro and in vivo chemosensitivity. Anticancer Res 12 : 1055-1061, 1992
  12. Gwak HS, Youn SM, Kwon AH, Lee SH, Kim JH, Rhee CH : ACNU-cisplatin continuous infusion chemotherapy as salvage therapy for recurrent glioblastomas : phase II study. J Neurooncol 75 : 173-180, 2005 https://doi.org/10.1007/s11060-005-1858-8
  13. Hasegawa Y, Goto M, Hanai N, Ijichi K, Adachi M, Terada A, et al. : Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer. Oral Oncol 43 : 749-756, 2007 https://doi.org/10.1016/j.oraloncology.2006.09.003
  14. Haselsberger K, Peterson DC, Thomas DG, Darling JL : Assay of anticancer drugs in tissue culture : comparison of a tetrazolium-based assay and a protein binding dye assay in short-term cultures derived from human malignant glioma. Anticancer Drugs 7 : 331-338, 1996 https://doi.org/10.1097/00001813-199605000-00014
  15. Hirano Y, Ushiyama T, Suzuki K, Fujita K : Clinical application of an in vitro chemosensitivity test, the Histoculture Drug Response Assay, to urological cancers : wide distribution of inhibition rates in bladder cancer and renal cell cancer. Urol Res 27 : 483-488, 1999 https://doi.org/10.1007/s002400050139
  16. Hochberg FH, Parker LM, Takvorian T, Canellos GP, Zervas NT : High-dose BCNU with autologous bone marrow rescue for recurrent glioblastoma multiforme. J Neurosurg 54 : 455-460, 1981 https://doi.org/10.3171/jns.1981.54.4.0455
  17. Iwadate Y, Fujimoto S, Namba H, Yamaura A : Promising survival for patients with glioblastoma multiforme treated with individualised chemotherapy based on in vitro drug sensitivity testing. Br J Cancer 89 : 1896-1900, 2003 https://doi.org/10.1038/sj.bjc.6601376
  18. Kanasugi M, Aoki D, Suzuki N, Susumu N, Nakata S, Horiuchi M, et al. : Sensitivity to cisplatin determined by the histoculture drug response assay and clinical response of endometrial cancer. Int J Gynecol Cancer 16 : 409-415, 2006 https://doi.org/10.1111/j.1525-1438.2006.00409.x
  19. Kim IK, Yoo H, Shin SH, Youn SM, Rhee CH, Lee SH, et al. : Histoculture drug response assay for brain tumors : a preliminary study for evaluability and compatibility. J Korean Brain Tumor Soc 9 : 67-73, 2010
  20. Kim JC, Kim DD, Lee YM, Kim TW, Cho DH, Kim MB, et al. : Evaluation of novel histone deacetylase inhibitors as therapeutic agents for colorectal adenocarcinomas compared to established regimens with the histoculture drug response assay. Int J Colorectal Dis 24 : 209-218, 2009 https://doi.org/10.1007/s00384-008-0590-1
  21. Kochii M, Kitamura I, Goto T, Nishi T, Takeshima H, Saito Y, et al. : Randomized comparison of intra-arterial versus intravenous infusion of ACNU for newly diagnosed patients with glioblastoma. J Neurooncol 49 : 63-70, 2000 https://doi.org/10.1023/A:1006457502972
  22. Kodera Y, Ito S, Fujiwara M, Mochizuki Y, Ohashi N, Ito Y, et al. : In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues. Int J Clin Oncol 11 : 449-453, 2006 https://doi.org/10.1007/s10147-006-0618-x
  23. Kubota T, Sasano N, Abe O, Nakao I, Kawamura E, Saito T, et al. : Potential of the histoculture drug-response assay to contribute to cancer patient survival. Clin Cancer Res 1 : 1537-1543, 1995
  24. Lassen U, Kristjansen PE, Wagner A, Kosteljanetz M, Poulsen HS : Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study. J Neurooncol 43 : 161-166, 1999 https://doi.org/10.1023/A:1006254716877
  25. Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, et al. : Modified procarbazine, CCNU, and vincristine (PCV 3) combination chemotherapy in the treatment of malignant brain tumors. Cancer Treat Rep 64 : 237-244, 1980
  26. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG : Response criteria for phase III studies of supratentorial malignant glioma. J Clin Oncol 8 : 1277-1280, 1990 https://doi.org/10.1200/JCO.1990.8.7.1277
  27. Morioka H, Yabe H, Morii T, Yamada R, Kato S, Yuasa S, et al. : In vitro chemosensitivity of human soft tissue sarcoma. Anticancer Res 21 : 4147-4151, 2001
  28. Mosmann T : Rapid colorimetric assay for cellular growth and survival : application to proliferation and cytotoxicity assays. J Immunol Methods 65 : 55-63, 1983 https://doi.org/10.1016/0022-1759(83)90303-4
  29. Nakada S, Aoki D, Ohie S, Horiuchi M, Suzuki N, Kanasugi M, et al. : Chemosensitivity testing of ovarian cancer using the histoculture drug response assay : sensitivity to cisplatin and clinical response. Int J Gynecol Cancer 15 : 445-452, 2005 https://doi.org/10.1111/j.1525-1438.2005.15307.x
  30. Ohie S, Udagawa Y, Kozu A, Komuro Y, Aoki D, Nozawa S, et al. : Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide. Anticancer Res 20 : 2049-2054, 2000
  31. Pathak KA, Juvekar AS, Radhakrishnan DK, Deshpande MS, Pai VR, Chaturvedi P, et al. : In vitro chemosensitivity profile of oral squamous cell cancer and its correlation with clinical response to chemotherapy. Indian J Cancer 44 : 142-146, 2007 https://doi.org/10.4103/0019-509X.39376
  32. Poortmans PM, Kluin-Nelemans HC, Haaxma-Reiche H, Van't Veer M, Hansen M, Soubeyran P, et al. : High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma : European Organization for Research and Treatment of Cancer Lymphoma Group Phase II Trial 20962. J Clin Oncol 21 : 4483-4488, 2003 https://doi.org/10.1200/JCO.2003.03.108
  33. Qin D, Ou G, Mo H, Song Y, Kang G, Hu Y, et al. : Improved efficacy of chemotherapy for glioblastoma by radiation-induced opening of blood-brain barrier : clinical results. Int J Radiat Oncol Biol Phys 51 : 959-962, 2001 https://doi.org/10.1016/S0360-3016(01)01735-7
  34. Sanson M, Ameri A, Monjour A, Sahmoud T, Ronchin P, Poisson M, et al. : Treatment of recurrent malignant supratentorial gliomas with ifosfamide, carboplatin and etoposide : a phase II study. Eur J Cancer 32A : 2229-2235, 1996
  35. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR : American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol 22 : 3631-3638, 2004 https://doi.org/10.1200/JCO.2004.05.065
  36. Singh B, Li R, Xu L, Poluri A, Patel S, Shaha AR, et al. : Prediction of survival in patients with head and neck cancer using the histoculture drug response assay. Head Neck 24 : 437-442, 2002 https://doi.org/10.1002/hed.10066
  37. Skalski V, Rivas J, Panasci L, McQuillan A, Feindel W : The cytotoxicity of sarcosinamide chloroethylnitrosourea (SarCNU) and BCNU in primary gliomas and glioma cell lines : analysis of data in reference to theoretical peak plasma concentrations in man. Cancer Chemother Pharmacol 22 : 137-140, 1988
  38. Stewart LA : Chemotherapy in adult high-grade glioma : a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359 : 1011-1018, 2002 https://doi.org/10.1016/S0140-6736(02)08091-1
  39. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al. : Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 : 987-996, 2005 https://doi.org/10.1056/NEJMoa043330
  40. Suda S, Akiyama S, Sekiguchi H, Kasai Y, Ito K, Nakao A : Evaluation of the histoculture drug response assay as a sensitivity test for anticancer agents. Surg Today 32 : 477-481, 2002 https://doi.org/10.1007/s005950200080
  41. Vescio RA, Connors KM, Kubota T, Hoffman RM : Correlation of histology and drug response of human tumors grown in native-state three-dimensional histoculture and in nude mice. Proc Natl Acad Sci U S A 88 : 5163-5166, 1991 https://doi.org/10.1073/pnas.88.12.5163
  42. Vescio RA, Redfern CH, Nelson TJ, Ugoretz S, Stern PH, Hoffman RM : In vivo-like drug responses of human tumors growing in three-dimensional gel-supported primary culture. Proc Natl Acad Sci U S A 84 : 5029-5033, 1987 https://doi.org/10.1073/pnas.84.14.5029
  43. Weaver JR, Wientjes MG, Au JL : Regional heterogeneity and pharmacodynamics in human solid tumor histoculture. Cancer Chemother Pharmacol 44 : 335-342, 1999 https://doi.org/10.1007/s002800050986
  44. Wen PY, Kesari S : Malignant gliomas in adults. N Engl J Med 359 : 492-507, 2008 https://doi.org/10.1056/NEJMra0708126
  45. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, et al. : Updated response assessment criteria for high-grade gliomas : response assessment in neuro-oncology working group. J Clin Oncol 28 : 1963-1972, 2010 https://doi.org/10.1200/JCO.2009.26.3541
  46. Yamauchi M, Satta T, Ito A, Kondo T, Takagi H : A feasibility study of the SDI test for the evaluation of gastrointestinal cancer sensitivity to anticancer drugs. J Surg Oncol 47 : 253-260, 1991 https://doi.org/10.1002/jso.2930470410
  47. Yoshimasu T, Oura S, Hirai I, Tamaki T, Kokawa Y, Hata K, et al. : Data acquisition for the histoculture drug response assay in lung cancer. J Thorac Cardiovasc Surg 133 : 303-308, 2007 https://doi.org/10.1016/j.jtcvs.2006.06.030
  48. Yung WK : In vitro chemosensitivity testing and its clinical application in human gliomas. Neurosurg Rev 12 : 197-203, 1989 https://doi.org/10.1007/BF01743984
  49. Yung WK, Janus TJ, Maor M, Feun LG : Adjuvant chemotherapy with carmustine and cisplatin for patients with malignant gliomas. J Neurooncol 12 : 131-135, 1992

Cited by

  1. Long Noncoding RNA MRUL Promotes ABCB1 Expression in Multidrug-Resistant Gastric Cancer Cell Sublines vol.34, pp.17, 2011, https://doi.org/10.1128/mcb.01580-13
  2. Intra-arterial carboplatin as a salvage strategy in the treatment of recurrent glioblastoma multiforme vol.119, pp.2, 2011, https://doi.org/10.1007/s11060-014-1504-4
  3. Multidrug-Resistance Related Long Non-Coding RNA Expression Profile Analysis of Gastric Cancer vol.10, pp.8, 2015, https://doi.org/10.1371/journal.pone.0135461
  4. Validation of a preclinical model for assessment of drug efficacy in melanoma vol.7, pp.11, 2011, https://doi.org/10.18632/oncotarget.7541
  5. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells vol.14, pp.None, 2011, https://doi.org/10.1186/s12967-016-0803-2
  6. Pleomorphism and drug resistant cancer stem cells are characteristic of aggressive primary meningioma cell lines vol.17, pp.None, 2011, https://doi.org/10.1186/s12935-017-0441-7